Oral PCSK9 Inhibitor Shows Encouraging LDL Lowering
A new oral formulation of a PCSK9-inhibitor, cholesterol-lowering drug has shown encouraging results in a phase 2 study.
United States Baylor College Of Medicine Coll Cardiol Christie Ballantyne Rhonda Cooper Denka Seiken
Source: medscape.com